Dec 31 - Novavax Inc said on Friday it had submitted data to the U.S. Food and Drug Administration for emergency use authorization of its COVID-19 vaccine, with the company expecting to submit a formal request in one month. (Reporting by Leroy Leo in Bengaluru; Editing by Aditya Soni)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.055 USD | +2.66% | +1.39% | -16.15% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.15% | 553M | |
+1.48% | 42.59B | |
+7.92% | 40.65B | |
+48.66% | 40.57B | |
-11.96% | 26.77B | |
+7.94% | 24.81B | |
-24.76% | 18.17B | |
+29.12% | 12.05B | |
-2.70% | 11.7B | |
+7.23% | 11.1B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax submits data to U.S. FDA for COVID-19 vaccine